Literature DB >> 18276118

No association between global leukocyte DNA methylation and homocysteine levels in schizophrenia patients.

A Bromberg1, J Levine, B Nemetz, R H Belmaker, G Agam.   

Abstract

Meta-analysis recently suggested that a 5 muM increase in homocysteine is associated with a 70% higher risk for schizophrenia. Elevated homocysteine is reported to alter macromolecule methylation. We studied whether elevated plasma homocysteine levels in schizophrenia are associated with altered leukocyte global DNA methylation. DNA was extracted from peripheral blood leukocytes of 28 schizophrenia patients vs. 26 matched healthy controls. Percent of global genome DNA methylation was measured using the cytosine-extension method. Homocysteine levels were higher in schizophrenia patients than in controls. No difference in global DNA methylation between schizophrenia patients and control subjects was found (74.0%+/-14.8 vs. 69.4+/-22.0, p=0.31). A significant interaction between diagnosis and smoking on DNA methylation was obtained (F=6.8, df=1,47, p=0.032). Although leukocytes may be a useful cell model to evaluate epigenetic changes such as global DNA methylation in brain, future studies should compare global DNA methylation in peripheral tissue vs. brain in laboratory animals.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18276118     DOI: 10.1016/j.schres.2008.01.009

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  23 in total

1.  DAT1 Gene Methylation as an Epigenetic Biomarker in Attention Deficit Hyperactivity Disorder: A Commentary.

Authors:  Erika Tonelli; Esterina Pascale; Miriam Troianiello; Claudio D'Addario; Walter Adriani
Journal:  Front Genet       Date:  2020-05-11       Impact factor: 4.599

Review 2.  Histone modifications, DNA methylation, and schizophrenia.

Authors:  David P Gavin; Rajiv P Sharma
Journal:  Neurosci Biobehav Rev       Date:  2009-10-30       Impact factor: 8.989

3.  Chromatin from peripheral blood mononuclear cells as biomarkers for epigenetic abnormalities in schizophrenia.

Authors:  David P Gavin; Rajiv P Sharma
Journal:  Cardiovasc Psychiatry Neurol       Date:  2009-07-22

4.  Epigenetic mechanisms in the pathophysiology of psychotic disorders.

Authors:  W Brad Ruzicka
Journal:  Harv Rev Psychiatry       Date:  2015 May-Jun       Impact factor: 3.732

5.  Antipsychotic Medications and DNA Methylation in Schizophrenia and Bipolar Disorder: A Systematic Review.

Authors:  Kyle J Burghardt; Audrey S Khoury; Zaher Msallaty; Zhengping Yi; Berhane Seyoum
Journal:  Pharmacotherapy       Date:  2020-03-09       Impact factor: 4.705

6.  Dimethylated lysine 9 of histone 3 is elevated in schizophrenia and exhibits a divergent response to histone deacetylase inhibitors in lymphocyte cultures.

Authors:  David P Gavin; Cherise Rosen; Kayla Chase; Dennis R Grayson; Nguwah Tun; Rajiv P Sharma
Journal:  J Psychiatry Neurosci       Date:  2009-05       Impact factor: 6.186

Review 7.  The epigenome and postnatal environmental influences in psychotic disorders.

Authors:  Ehsan Pishva; Gunter Kenis; Daniel van den Hove; Klaus-Peter Lesch; Marco P M Boks; Jim van Os; Bart P F Rutten
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2014-02-19       Impact factor: 4.328

8.  Plasma total homocysteine is associated with DNA methylation in patients with schizophrenia.

Authors:  Makoto Kinoshita; Shusuke Numata; Atsushi Tajima; Shinji Shimodera; Issei Imoto; Tetsuro Ohmori
Journal:  Epigenetics       Date:  2013-04-26       Impact factor: 4.528

9.  Dietary intake, plasma homocysteine, and repetitive element DNA methylation in the Multi-Ethnic Study of Atherosclerosis (MESA).

Authors:  W Perng; E Villamor; M R Shroff; J A Nettleton; J R Pilsner; Y Liu; A V Diez-Roux
Journal:  Nutr Metab Cardiovasc Dis       Date:  2013-12-25       Impact factor: 4.222

Review 10.  The dynamics of DNA methylation in schizophrenia and related psychiatric disorders.

Authors:  Dennis R Grayson; Alessandro Guidotti
Journal:  Neuropsychopharmacology       Date:  2012-09-05       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.